First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors
Clinical trial NCT05054348 · COMPLETED
Trial details
- NCT number
- NCT05054348
- Sponsor
- Immune-Onc Therapeutics
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-30
- Primary completion
- 2024-04-29
- Enrollment
- 91
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.